<p>诺和诺德 A/V NYSE: NVO 股票正在考验买入持有投资者的耐心。在过去五年中，NVO 股票上涨超过 200%。然而，在过去一年中，它下跌超过 61%，在 2025 年下跌超过 43%。即使在波动的医疗股票领域，这种表现不佳也无法被忽视。</p>
<p>但目前让股东感到焦虑的是公司最近下调了全年指引，这导致股票在不到一周的时间内下跌了 3%。</p>
<p>获取 <strong>Novo Nordisk A/S</strong> 的提醒：</p>
<p>诺和诺德将其销售增长预期下调至 8% 到 14% 的区间。该区间的高端现在与之前 13% 到 21% 的指引的低端一致。公司修订后的营业利润指引也出现类似情况，现在在 10% 到 16% 的区间内，低于之前的 16% 到 24%。</p>
<p>然而，增长即便减少仍然是增长，在许多股票似乎被高估的时刻，NVO 股票并没有被高估。不过，长期投资者是否该抛售 NVO 股票呢？</p>
<h2>新任 CEO 面临熟悉的问题</h2>
<p>诺和诺德最近宣布任命新首席执行官（CEO）Maziar Mike Doustdar，他将在 8 月 6 日正式接任。Doustdar 面临的第一个问题是 <strong>复合 GLP-1 药物的持续威胁</strong>，这些药物正在侵蚀公司的市场份额和增长。这在 Hims &amp; Hers Health Inc. NYSE: HIMS 在 2025 年的激增中尤为明显。</p>
<p>虽然复合 GLP-1 药物无疑是公司增长的问题，但并不是唯一的问题。诺和诺德还提到国际市场的 “渗透率低于预期” 和来自 Eli Lilly &amp; Co. NYSE: LLY 的竞争，该公司在临床疗效和市场份额上持续取得进展。</p>
<h2>显著的减重是有代价的</h2>
<p>复合 GLP-1 药物并不是一个新问题。诺和诺德和 Eli Lilly 自推出 GLP-1 药物以来几乎一直面临这个问题。</p>
<p>主要问题是成本。大多数保险公司会覆盖 Ozempic（诺和诺德）和 Mounjaro（Eli Lilly）。这些药物被批准用于治疗 1 型糖尿病（T1D），特别是血糖控制。由于糖尿病是一种慢性疾病，保险公司将这些药物视为符合明确的护理标准。</p>
<p>Wegovy 和 Zepbound 的保险覆盖则不那么一致，这两种药物是公司针对肥胖的 GLP-1 药物。一个更显著的危险是 Medicare 不覆盖这些药物。</p>
<p>没有保险覆盖，这些药物可能会让患者承担高昂的费用，这使得复合 GLP-1 药物成为寻求这些药物好处的患者的替代选择。通常，复合 GLP-1 药物的价格可以比品牌产品低 <strong>50%-70%</strong>。</p>
<p>然而，另一个问题是复合药物为何会出现在市场上。由于这些药物在一个超出预期的可寻址市场中的压倒性受欢迎程度，超出了诺和诺德或 Eli Lilly 的承受能力。</p>
<p>这使得食品药品监督管理局（FDA）宣布短缺，允许在某些条件下合法复合 GLP-1 药物。然而，这与 FDA 批准并不相同——这是诺和诺德强调的一个区别。复合版本存在风险，其中许多风险仍然难以量化。</p>
<p>诺和诺德已提起九起诉讼，试图阻止复合替代品的增长，但到目前为止，公司并没有看到任何影响，尽管 FDA 已告知药品制造商停止生产复合产品，因为 Wegovy 等产品的短缺已经结束。</p>
<h2>盈利将是下一个上涨或下跌的关键</h2>
<p>无论投资者站在哪一方，获得更多的清晰度不会太久。<strong>诺和诺德将在 8 月 6 日市场开盘前公布财报</strong>。财报应该能回答一个简单的问题，过去 30 天股票下跌超过 29%，过去一周下跌超过 3%。</p>
<p>抛售是否过度？</p>
<p>如果公司的业绩超出预期或与其预测相符，投资者可能会有一个 <strong>买入机会</strong>。NVO 股票目前的交易价格约为未来收益的 12 倍，并且相较于其历史平均水平存在折扣。</p>
<p>这也使其相较于行业平均水平略有折扣。</p>
<p>在这样的抛售中，容易忽视基本面。然而，诺和诺德仍然是一家非常盈利的公司，年复一年（YOY）收入和盈利均在增长。</p>
<p>投资者还应记住，Ozempic 和 Wegovy 的市场巨大，这将为许多公司提供竞争空间。</p>
<p>然而，在短期内，公司和投资者需要克服短期障碍。NVO 股票的交易价格远低于其 50 日简单移动平均线（SMA），这已经成为股票的阻力区域。然而，卖出量似乎正在减弱，且相对强弱指数（RSI）显示超卖状态，<strong>底部可能正在形成</strong>。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20250804114947_nvo841.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20250804114947_nvo841.png"/></p>
<h2>你现在应该投资 1,000 美元在诺和诺德 A/S 吗？</h2>
<p>在考虑诺和诺德 A/S 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而诺和诺德 A/S 并不在名单上。</p>
<p>虽然诺和诺德 A/S 目前在分析师中获得持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票的详情</p>

诺和诺德公司

<p>诺和诺德公司的股票在 2025 年下跌超过 43%，过去一年下降了 61%，这主要归因于疲软的业绩指引和来自 GLP-1 药物的竞争。该公司将销售增长预期修订为 8%-14%，运营利润预期为 10%-16%。新任首席执行官 Maziar Mike Doustdar 面临来自复合 GLP-1 药物和礼来公司的竞争挑战。财报将于 8 月 6 日公布，这可能会澄清股票的未来方向。目前，尽管诺和诺德是一家盈利能力强且市场潜力巨大的公司，其股票仍以折扣价交易</p>

<p>Novo Nordisk A/V NYSE: NVO stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than 43% in 2025. Even in the volatile medical stocks sector, that kind of underperformance can’t be overlooked.</p>
<div class="lb-trans"><p>诺和诺德 A/V NYSE: NVO 股票正在考验买入持有投资者的耐心。在过去五年中，NVO 股票上涨超过 200%。然而，在过去一年中，它下跌超过 61%，在 2025 年下跌超过 43%。即使在波动的医疗股票领域，这种表现不佳也无法被忽视。</p>
</div><p>But what’s making shareholders anxious right now is the company’s recent slash of full-year guidance, which caused the stock to drop by 3% in less than a week.</p>
<div class="lb-trans"><p>但目前让股东感到焦虑的是公司最近下调了全年指引，这导致股票在不到一周的时间内下跌了 3%。</p>
</div><p>Get <strong>Novo Nordisk A/S</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Novo Nordisk A/S</strong> 的提醒：</p>
</div><p>Novo Nordisk cut its sales growth expectations to a range of 8% and 14%. The high end of that range is now consistent with the low end of the previous guidance of 13% to 21%. A similar story emerged with the company’s revised guidance for operating profit, which is now in a range of 10% to 16%, down from 16% to 24%.</p>
<div class="lb-trans"><p>诺和诺德将其销售增长预期下调至 8% 到 14% 的区间。该区间的高端现在与之前 13% 到 21% 的指引的低端一致。公司修订后的营业利润指引也出现类似情况，现在在 10% 到 16% 的区间内，低于之前的 16% 到 24%。</p>
</div><p>However, less growth is still growth, and at a time when many stocks seem overvalued, NVO stock does not. Still, is it time for long-term investors to shed NVO stock?</p>
<div class="lb-trans"><p>然而，增长即便减少仍然是增长，在许多股票似乎被高估的时刻，NVO 股票并没有被高估。不过，长期投资者是否该抛售 NVO 股票呢？</p>
</div><h2>A New CEO Faces a Familiar Problem</h2>
<div class="lb-trans"><h2>新任 CEO 面临熟悉的问题</h2>
</div><p>Novo Nordisk recently announced the appointment of a new chief executive officer (CEO), Maziar Mike Doustdar, who officially takes the reins on August 6. One of the first problems Doustdar faces is the <strong>continuing threat from compounded GLP-1 drugs</strong> that are eating away at the company’s market share and growth. This is particularly evident in the surge in Hims &amp; Hers Health Inc. NYSE: HIMS in 2025.</p>
<div class="lb-trans"><p>诺和诺德最近宣布任命新首席执行官（CEO）Maziar Mike Doustdar，他将在 8 月 6 日正式接任。Doustdar 面临的第一个问题是 <strong>复合 GLP-1 药物的持续威胁</strong>，这些药物正在侵蚀公司的市场份额和增长。这在 Hims &amp; Hers Health Inc. NYSE: HIMS 在 2025 年的激增中尤为明显。</p>
</div><p>While compounded GLP-1s are undoubtedly an issue for the company's growth, they're not the only issue. Novo Nordisk also cited “lower-than-expected penetration” in international markets and the competition from Eli Lilly &amp; Co. NYSE: LLY, which continues to make gains in clinical efficacy and market share.</p>
<div class="lb-trans"><p>虽然复合 GLP-1 药物无疑是公司增长的问题，但并不是唯一的问题。诺和诺德还提到国际市场的 “渗透率低于预期” 和来自 Eli Lilly &amp; Co. NYSE: LLY 的竞争，该公司在临床疗效和市场份额上持续取得进展。</p>
</div><h2>Significant Weight Loss Comes at a Price</h2>
<div class="lb-trans"><h2>显著的减重是有代价的</h2>
</div><p>Compounded GLP-1 drugs aren’t a new problem. Novo Nordisk and Eli Lilly have been facing this issue almost since they launched their GLP-1 drugs.</p>
<div class="lb-trans"><p>复合 GLP-1 药物并不是一个新问题。诺和诺德和 Eli Lilly 自推出 GLP-1 药物以来几乎一直面临这个问题。</p>
</div><p>The primary issue is cost. Most insurance companies will cover Ozempic (Novo Nordisk) and Mounjaro (Eli Lilly). These drugs are approved for the treatment of Type-1 diabetes (T1D), specifically glycemic control. Since diabetes is a chronic condition, insurers view these drugs as consistent with clear standards of care.</p>
<div class="lb-trans"><p>主要问题是成本。大多数保险公司会覆盖 Ozempic（诺和诺德）和 Mounjaro（Eli Lilly）。这些药物被批准用于治疗 1 型糖尿病（T1D），特别是血糖控制。由于糖尿病是一种慢性疾病，保险公司将这些药物视为符合明确的护理标准。</p>
</div><p>Insurance coverage is less consistent for Wegovy and Zepbound, which are the companies’ respective GLP-1 drugs for obesity. A more prominent danger is that Medicare does not cover these drugs.</p>
<div class="lb-trans"><p>Wegovy 和 Zepbound 的保险覆盖则不那么一致，这两种药物是公司针对肥胖的 GLP-1 药物。一个更显著的危险是 Medicare 不覆盖这些药物。</p>
</div><p>Without insurance coverage, these drugs can be cost-prohibitive, which makes compounded GLP-1 drugs an alternative for patients looking for the benefits of these drugs. Frequently, compounded GLP-1 drugs can be obtained for <strong>50%-70% less than the branded products</strong>.</p>
<div class="lb-trans"><p>没有保险覆盖，这些药物可能会让患者承担高昂的费用，这使得复合 GLP-1 药物成为寻求这些药物好处的患者的替代选择。通常，复合 GLP-1 药物的价格可以比品牌产品低 <strong>50%-70%</strong>。</p>
</div><p>However, another issue is why the compounded drugs are on the market to begin with. The overwhelming popularity of these drugs in a larger-than-expected addressable market was greater than Novo Nordisk or Eli Lilly could handle.</p>
<div class="lb-trans"><p>然而，另一个问题是复合药物为何会出现在市场上。由于这些药物在一个超出预期的可寻址市场中的压倒性受欢迎程度，超出了诺和诺德或 Eli Lilly 的承受能力。</p>
</div><p>That allowed the Food &amp; Drug Administration (FDA) to declare a shortage, permitting the legal compounding of GLP-1 drugs under certain conditions. However, this is not the same as FDA approval—a distinction Novo Nordisk emphasizes. Compounded versions carry risks, many of which remain hard to quantify.</p>
<div class="lb-trans"><p>这使得食品药品监督管理局（FDA）宣布短缺，允许在某些条件下合法复合 GLP-1 药物。然而，这与 FDA 批准并不相同——这是诺和诺德强调的一个区别。复合版本存在风险，其中许多风险仍然难以量化。</p>
</div><p>Novo Nordisk has filed nine lawsuits to try to stop the growth of compounded alternatives, but so far, the company is not seeing any impact, even though the FDA told drug makers to stop producing their compounded products now that the shortage of products like Wegovy has ended.</p>
<div class="lb-trans"><p>诺和诺德已提起九起诉讼，试图阻止复合替代品的增长，但到目前为止，公司并没有看到任何影响，尽管 FDA 已告知药品制造商停止生产复合产品，因为 Wegovy 等产品的短缺已经结束。</p>
</div><h2>Earnings Will Be the Next Leg Up or Down</h2>
<div class="lb-trans"><h2>盈利将是下一个上涨或下跌的关键</h2>
</div><p>Whatever side of the debate investors stand on, it won’t be long until they get more clarity. <strong>Novo Nordisk reports earnings on August 6</strong> before the market opens. The earnings report should answer a simple question, with the stock down more than 29% in the last 30 days and over 3% in the last week.</p>
<div class="lb-trans"><p>无论投资者站在哪一方，获得更多的清晰度不会太久。<strong>诺和诺德将在 8 月 6 日市场开盘前公布财报</strong>。财报应该能回答一个简单的问题，过去 30 天股票下跌超过 29%，过去一周下跌超过 3%。</p>
</div><p>Is the sell-off overdone?</p>
<div class="lb-trans"><p>抛售是否过度？</p>
</div><p>If the company's results exceed expectations or are just in line with their forecast, investors might have a <strong>buying opportunity</strong>. NVO stock is now trading around 12x forward earnings and is trading at a discount to its historical averages.</p>
<div class="lb-trans"><p>如果公司的业绩超出预期或与其预测相符，投资者可能会有一个 <strong>买入机会</strong>。NVO 股票目前的交易价格约为未来收益的 12 倍，并且相较于其历史平均水平存在折扣。</p>
</div><p>That also puts it at a slight discount to the sector average.</p>
<div class="lb-trans"><p>这也使其相较于行业平均水平略有折扣。</p>
</div><p>During sell-offs like this, it’s easy to overlook fundamentals. However, Novo Nordisk is still a very profitable company, increasing revenue and earnings year-over-year (YOY).</p>
<div class="lb-trans"><p>在这样的抛售中，容易忽视基本面。然而，诺和诺德仍然是一家非常盈利的公司，年复一年（YOY）收入和盈利均在增长。</p>
</div><p>Investors should also remember that the market for Ozempic and Wegovy is massive, which will allow room for many companies to compete.</p>
<div class="lb-trans"><p>投资者还应记住，Ozempic 和 Wegovy 的市场巨大，这将为许多公司提供竞争空间。</p>
</div><p>However, in the near term, the company and investors will need to work through short-term obstacles. NVO stock is trading well below its 50-day simple moving average (SMA), which has already been an area of resistance for the stock. However, the selling volume appears to be tapering off, and with an RSI indicating oversold conditions, <strong>a bottom may be forming</strong>.</p>
<div class="lb-trans"><p>然而，在短期内，公司和投资者需要克服短期障碍。NVO 股票的交易价格远低于其 50 日简单移动平均线（SMA），这已经成为股票的阻力区域。然而，卖出量似乎正在减弱，且相对强弱指数（RSI）显示超卖状态，<strong>底部可能正在形成</strong>。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20250804114947_nvo841.png" alt="" original-src="https://www.marketbeat.com/logos/articles/med_20250804114947_nvo841.png"/></p>
<h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在诺和诺德 A/S 吗？</h2>
</div><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑诺和诺德 A/S 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而诺和诺德 A/S 并不在名单上。</p>
</div><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺和诺德 A/S 目前在分析师中获得持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票的详情</p>
</div>

诺和诺德公司的股票下跌——底部是否终于出现了？